Market Cap 92.15M
Revenue (ttm) 70,000.00
Net Income (ttm) -84.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -121,357.14%
Debt to Equity Ratio 0.00
Volume 589,671
Avg Vol 2,513,146
Day's Range N/A - N/A
Shares Out 82.27M
Stochastic %K 16%
Beta 1.48
Analysts Sell
Price Target $5.83

Company Profile

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-...

Industry: Biotechnology
Sector: Healthcare
Phone: 267 440 4200
Address:
660 West Germantown Pike, Suite 110, Plymouth Meeting, United States
Lookingdown
Lookingdown Jul. 21 at 7:56 PM
$INO DNA-delivered immunotherapy shows promise for ovarian cancer 21 Jul, 2026 https://www.labmate-online.com/news/laboratory-research-news/126/the-wistar-institute/dna-delivered-immunotherapy-shows-promise-for-ovarian-cancer/68110
0 · Reply
Nordica
Nordica Jul. 21 at 6:35 PM
$INO Just two interesting questions to pose to Google Gemini regarding the degradation of immune responses with time. For RRP patients their concerns extend for a lifetime. 1) "both INO-3107 and Papzimeos appear to generate long term patient benefit. do we have any idea if the benefit will degrade with time? 2) "Based on immune boosting therapies for other indications, those with longer clinical data tracking histories, what kind of senescence might be anticipated?"
1 · Reply
Waynoway
Waynoway Jul. 21 at 5:02 PM
$INO Nothing ever succeeds here
1 · Reply
Ihateboomers
Ihateboomers Jul. 21 at 4:16 PM
$INO $PGEN is ripping and the turd that is Inovio circling the drain. Just how it should be
0 · Reply
INOVIO
INOVIO Jul. 21 at 4:07 PM
$PGEN $INO Honest question for Precigen longs, is your investment thesis factoring in the possibility that INOVIO’s INO-3107 receives FDA approval in less than 3 months? If that happens, how do you think it affects the stock price? Smart investing usually means considering both sides of the equation. I want some real answers, not some “it won’t happen”… Again, its important as investors to weigh all the risks and I want to know your thoughts around this. Thank you
2 · Reply
RajCx
RajCx Jul. 21 at 3:54 PM
$INO Since some people are questioning credibility of ApolloBio, I decided to ask GPT and here is what I got in summary.
0 · Reply
Tracker7
Tracker7 Jul. 21 at 3:47 PM
$INO Sheesh! I just keep reporting and blocking the idiotic bashers that continually create a new basher account every other day. ST needs a way to forever keep these trolls from ever creating a new account. You would think that if someone doesn’t believe in a particular stock, that the common sense thing to do, would be to leave and never come back, right? But, of course we all know that they are hired basement dwellers with nothing else better to do but waste all their time and efforts here. Seems like big pharma is hating the fact that DNA plasmid medicines will be hurting their future sales model forever.
1 · Reply
Ihateboomers
Ihateboomers Jul. 21 at 3:46 PM
$INO stfu tomato. I’ll tell you how they’ll “invest” it. In their salaries and to travel on the shareholders dime. Hey LD, I’m still waiting to hear how those conferences you posted about move the needle for this dogsh*t company.
0 · Reply
tomonota
tomonota Jul. 21 at 3:24 PM
$INO Those bleeding shorts! Why must I pay $1.09 for 1,900 sh. today when they offered 240,000 shares on 7/6/26 at $1.06? Why can't they just cover at the price they sold INO; (even though we are heading back to, i.e. $1.79 =3 mo. high, or $2.98= the 1 year high)? It's not easy trading with all these naked swimmers trying to corner the market for INO. I may have to wait until 8/11/26, the earnings conference date, to find out how the Board will invest our next $300 MM financing tranche, to roll out our life-saving pipeline products.
1 · Reply
Ihateboomers
Ihateboomers Jul. 21 at 3:13 PM
$INO sick dd boomer! So tell us, a decade later why did Apollobio delist in China and is now well regarded as a shitco? Them and Inovio are like peanut butter and jelly, lol
1 · Reply
Latest News on INO
Inovio files $300M mixed securities shelf

2026-07-02T20:05:10.000Z - 19 days ago

Inovio files $300M mixed securities shelf


Inovio Pharmaceuticals Transcript: AGM 2026

May 20, 2026, 9:00 AM EDT - 2 months ago

Inovio Pharmaceuticals Transcript: AGM 2026


Inovio Pharmaceuticals Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 2 months ago

Inovio Pharmaceuticals Earnings Call Transcript: Q1 2026


Inovio Pharmaceuticals Quarterly report: Q1 2026

May 13, 2026, 4:30 PM EDT - 2 months ago

Inovio Pharmaceuticals Quarterly report: Q1 2026


Inovio Pharmaceuticals Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 2 months ago

Inovio Pharmaceuticals Earnings release: Q1 2026


Inovio Pharmaceuticals Slides: Q1 2026

May 13, 2026, 4:30 PM EDT - 2 months ago

Inovio Pharmaceuticals Slides: Q1 2026


INOVIO to Participate in Upcoming Scientific Conferences

May 8, 2026, 8:05 AM EDT - 2 months ago

INOVIO to Participate in Upcoming Scientific Conferences


Inovio Pharmaceuticals Proxy statement: Proxy filing

Apr 7, 2026, 8:00 AM EDT - 3 months ago

Inovio Pharmaceuticals Proxy statement: Proxy filing


INOVIO Announces Pricing of $17.5 Million Public Offering

Apr 2, 2026, 8:55 AM EDT - 3 months ago

INOVIO Announces Pricing of $17.5 Million Public Offering


INOVIO Announces Proposed Public Offering

Apr 1, 2026, 8:05 PM EDT - 3 months ago

INOVIO Announces Proposed Public Offering


INOVIO to Participate in Upcoming Scientific Conference

Apr 1, 2026, 10:29 AM EDT - 3 months ago

INOVIO to Participate in Upcoming Scientific Conference


Inovio Pharmaceuticals Slides: Corporate presentation

Mar 23, 2026, 8:00 AM EDT - 4 months ago

Inovio Pharmaceuticals Slides: Corporate presentation


Inovio Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 4 months ago

Inovio Pharmaceuticals Earnings Call Transcript: Q4 2025


Inovio Pharmaceuticals Earnings release: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 4 months ago

Inovio Pharmaceuticals Earnings release: Q4 2025


Inovio Pharmaceuticals Annual report: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 4 months ago

Inovio Pharmaceuticals Annual report: Q4 2025


Inovio Pharmaceuticals Slides: Q4 2025

Mar 12, 2026, 4:30 PM EDT - 4 months ago

Inovio Pharmaceuticals Slides: Q4 2025


Inovio, Akeso announce clinical collaboration

2026-03-04T13:15:14.000Z - 4 months ago

Inovio, Akeso announce clinical collaboration


Inovio announces U.S. FDA accepted BLA for INO-3107

2025-12-29T13:10:42.000Z - 7 months ago

Inovio announces U.S. FDA accepted BLA for INO-3107


INOVIO Reports Inducement Grant Under Inducement Plan

Dec 19, 2025, 4:05 PM EST - 7 months ago

INOVIO Reports Inducement Grant Under Inducement Plan


INOVIO to Participate in December Investor Conferences

Nov 18, 2025, 8:05 AM EST - 8 months ago

INOVIO to Participate in December Investor Conferences


Inovio price target raised to $6 from $5 at Piper Sandler

2025-11-14T11:45:36.000Z - 8 months ago

Inovio price target raised to $6 from $5 at Piper Sandler


Inovio 13.16M share Spot Secondary priced at $1.90

2025-11-11T13:45:25.000Z - 9 months ago

Inovio 13.16M share Spot Secondary priced at $1.90


INOVIO Announces Pricing of $25 Million Public Offering

Nov 11, 2025, 8:40 AM EST - 9 months ago

INOVIO Announces Pricing of $25 Million Public Offering


Inovio announces common stock offering, no amount given

2025-11-10T23:20:12.000Z - 9 months ago

Inovio announces common stock offering, no amount given


Inovio Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 10, 2025, 4:30 PM EST - 9 months ago

Inovio Pharmaceuticals Earnings Call Transcript: Q3 2025


Inovio Pharmaceuticals Earnings release: Q3 2025

Nov 10, 2025, 4:30 PM EST - 9 months ago

Inovio Pharmaceuticals Earnings release: Q3 2025


Inovio Pharmaceuticals Quarterly report: Q3 2025

Nov 10, 2025, 4:30 PM EST - 9 months ago

Inovio Pharmaceuticals Quarterly report: Q3 2025


Inovio Pharmaceuticals Slides: Q3 2025

Nov 10, 2025, 4:30 PM EST - 9 months ago

Inovio Pharmaceuticals Slides: Q3 2025


Inovio completes rolling submission of BLA for INO-3107

2025-11-03T13:10:55.000Z - 9 months ago

Inovio completes rolling submission of BLA for INO-3107


Inovio Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Earnings Call Transcript: Q2 2025


Inovio Pharmaceuticals Earnings release: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Earnings release: Q2 2025


Inovio Pharmaceuticals Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Quarterly report: Q2 2025


INOVIO to Present at Upcoming Scientific Conference

Jul 7, 2025, 4:05 PM EDT - 1 year ago

INOVIO to Present at Upcoming Scientific Conference


Inovio Pharmaceuticals Slides: Corporate Presentation

Jun 17, 2025, 7:00 AM EDT - 1 year ago

Inovio Pharmaceuticals Slides: Corporate Presentation


Inovio Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Earnings Call Transcript: Q1 2025


Inovio Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Earnings release: Q1 2025


Inovio Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Quarterly report: Q1 2025


INOVIO to Present at Upcoming Scientific Conferences

Apr 9, 2025, 8:05 AM EDT - 1 year ago

INOVIO to Present at Upcoming Scientific Conferences


Inovio Pharmaceuticals Proxy statement: Proxy Filing

Apr 7, 2025, 8:00 AM EDT - 1 year ago

Inovio Pharmaceuticals Proxy statement: Proxy Filing


Inovio Pharmaceuticals Earnings Call Transcript: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Earnings Call Transcript: Q4 2024


Inovio Pharmaceuticals Earnings release: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Earnings release: Q4 2024


Inovio Pharmaceuticals Annual report: Q4 2024

Mar 18, 2025, 4:30 PM EDT - 1 year ago

Inovio Pharmaceuticals Annual report: Q4 2024


Lookingdown
Lookingdown Jul. 21 at 7:56 PM
$INO DNA-delivered immunotherapy shows promise for ovarian cancer 21 Jul, 2026 https://www.labmate-online.com/news/laboratory-research-news/126/the-wistar-institute/dna-delivered-immunotherapy-shows-promise-for-ovarian-cancer/68110
0 · Reply
Nordica
Nordica Jul. 21 at 6:35 PM
$INO Just two interesting questions to pose to Google Gemini regarding the degradation of immune responses with time. For RRP patients their concerns extend for a lifetime. 1) "both INO-3107 and Papzimeos appear to generate long term patient benefit. do we have any idea if the benefit will degrade with time? 2) "Based on immune boosting therapies for other indications, those with longer clinical data tracking histories, what kind of senescence might be anticipated?"
1 · Reply
Waynoway
Waynoway Jul. 21 at 5:02 PM
$INO Nothing ever succeeds here
1 · Reply
Ihateboomers
Ihateboomers Jul. 21 at 4:16 PM
$INO $PGEN is ripping and the turd that is Inovio circling the drain. Just how it should be
0 · Reply
INOVIO
INOVIO Jul. 21 at 4:07 PM
$PGEN $INO Honest question for Precigen longs, is your investment thesis factoring in the possibility that INOVIO’s INO-3107 receives FDA approval in less than 3 months? If that happens, how do you think it affects the stock price? Smart investing usually means considering both sides of the equation. I want some real answers, not some “it won’t happen”… Again, its important as investors to weigh all the risks and I want to know your thoughts around this. Thank you
2 · Reply
RajCx
RajCx Jul. 21 at 3:54 PM
$INO Since some people are questioning credibility of ApolloBio, I decided to ask GPT and here is what I got in summary.
0 · Reply
Tracker7
Tracker7 Jul. 21 at 3:47 PM
$INO Sheesh! I just keep reporting and blocking the idiotic bashers that continually create a new basher account every other day. ST needs a way to forever keep these trolls from ever creating a new account. You would think that if someone doesn’t believe in a particular stock, that the common sense thing to do, would be to leave and never come back, right? But, of course we all know that they are hired basement dwellers with nothing else better to do but waste all their time and efforts here. Seems like big pharma is hating the fact that DNA plasmid medicines will be hurting their future sales model forever.
1 · Reply
Ihateboomers
Ihateboomers Jul. 21 at 3:46 PM
$INO stfu tomato. I’ll tell you how they’ll “invest” it. In their salaries and to travel on the shareholders dime. Hey LD, I’m still waiting to hear how those conferences you posted about move the needle for this dogsh*t company.
0 · Reply
tomonota
tomonota Jul. 21 at 3:24 PM
$INO Those bleeding shorts! Why must I pay $1.09 for 1,900 sh. today when they offered 240,000 shares on 7/6/26 at $1.06? Why can't they just cover at the price they sold INO; (even though we are heading back to, i.e. $1.79 =3 mo. high, or $2.98= the 1 year high)? It's not easy trading with all these naked swimmers trying to corner the market for INO. I may have to wait until 8/11/26, the earnings conference date, to find out how the Board will invest our next $300 MM financing tranche, to roll out our life-saving pipeline products.
1 · Reply
Ihateboomers
Ihateboomers Jul. 21 at 3:13 PM
$INO sick dd boomer! So tell us, a decade later why did Apollobio delist in China and is now well regarded as a shitco? Them and Inovio are like peanut butter and jelly, lol
1 · Reply
BentleyT99
BentleyT99 Jul. 21 at 3:08 PM
0 · Reply
Ihateboomers
Ihateboomers Jul. 21 at 3:01 PM
$INO there’s no such thing as a quiet period during fda review. If they had good news to report it would have been announced yesterday. Bad news on the other hand, they’ll sit on that as long as legally possible
2 · Reply
Ihateboomers
Ihateboomers Jul. 21 at 2:51 PM
$INO whenever this clown posts, the stock is going lower. Just check his abysmal track record. How’s lunr doing Robert?
2 · Reply
rioe
rioe Jul. 21 at 2:37 PM
$INO For those on the sidelines, remember that the biggest moves often happen when expectations are low and news flow is quiet. Once the market starts pricing in the outcome, it can happen fast. Do your own research, know your risk, and don’t let the shorty noise distract you from investing here.🚀🚀
1 · Reply
GorillaofWallStreet
GorillaofWallStreet Jul. 21 at 2:28 PM
$INO Quote from Pumper Pat Carr. "BP has a lot to lose if Little INO gets traction."
0 · Reply
INOVIO
INOVIO Jul. 21 at 2:27 PM
$INO Company “Quite period” few months prior to FDA approval is normal , it means the FDA review is progressing as expected. INO-3107 has already cleared major milestones: BLA acceptance and mid-cycle review. From here, most of the work happens behind closed doors with labeling, inspections, and final FDA review. That’s why many biotech companies go quiet before a PDUFA decision. No daily headlines doesn’t mean nothing is happening. It often means everything is happening where it should be.
2 · Reply
CptHubes
CptHubes Jul. 21 at 1:27 PM
$INO these bears are annoying lol. They care way too much on a “0” stock
0 · Reply
updownsides
updownsides Jul. 21 at 1:08 AM
$INO @BentleyT99 Buttley has a new catch phrase now instead of, "We Got This." It's now, "Let's Roll!!!"
0 · Reply
Goldmember6
Goldmember6 Jul. 21 at 12:00 AM
$INO barry aka ford pinto bently where are you .. come out
0 · Reply
lolord
lolord Jul. 20 at 9:48 PM
$INO garbage junk not even a word , nothing being developed in the pipeline
0 · Reply
wallstbullinfinity
wallstbullinfinity Jul. 20 at 9:02 PM
$INO 🕚🕙🕑🧬🧬🧬🌏🌎🌍 RRP patients have waited long enough. They finally have science on their side, real data, a proven mechanism, a treatment that works. What they need now is a regulator with the institutional knowledge and confidence to act on it. ~ Kim RRP Foundation A second therapy, INOVIO's INO-3107, is now under FDA review on the accelerated approval pathway, with a decision expected October 30, 2026. More options. More patients who might be reached. https://www.linkedin.com/posts/kimmcclellanrrpf_rrp-recurrentrespiratorypapillomatosis-rarediseases-share-7460028460204290048-P3Li?utm_source=social_share_send&utm_medium=android_app&rcm=ACoAAEBu0csB_wEDGPgiEW9Thc6ko65C1_INkN0&utm_campaign=copy_link
2 · Reply
Nordica
Nordica Jul. 20 at 8:02 PM
$INO I just encourage a sense of urgency, both for VGX in China, for RRP in USA, for all of Inovios endeavors... Competition ramps up, leaders in a race are caught from behind, cutthroat is norm. But I guess paramount is a single first product success. Achievement of this mark, legitimizes the company. Until that time, the company is just a backwater research lab. At the very least, get Cellectra approved as a device.
0 · Reply